| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD23; FCE2; CD23A; IGEBF; CLEC4J; FCER2 |
| Entrez GeneID | 2208 |
| clone | 5B5 |
| WB Predicted band size | 37kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FCER2 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL12B抗体的参考文献及摘要概括：
1. **"Targeting IL-12/IL-23p40 in immune-mediated diseases"**
*作者：Trinchieri G, et al. (2018)*
**摘要**：综述了IL-12和IL-23的p40亚基(IL12B编码)在银屑病、炎症性肠病等疾病中的核心作用，重点讨论了针对p40的单克隆抗体(如ustekinumab)的临床疗效及作用机制。
2. **"Ustekinumab as induction and maintenance therapy for Crohn's disease"**
*作者：Sandborn WJ, et al. (2016)*
**摘要**：通过随机对照试验验证抗IL12B抗体ustekinumab在克罗恩病患者中的疗效，证明其可显著缓解症状并维持长期临床缓解。
3. **"Structural basis for IL-12 and IL-23 receptor sharing by a novel cytokine antibody"**
*作者：Kasperkovitz PV, et al. (2010)*
**摘要**：解析了IL12B抗体通过阻断IL-12与IL-23共有的p40亚基与受体结合的分子机制，为优化抗体药物设计提供结构学依据。
4. **"IL-12p40-dependent immune regulation in autoimmune encephalomyelitis"**
*作者：Becher B, et al. (2002)*
**摘要**：利用IL12B基因敲除小鼠及抗IL12B抗体，证明IL-12p40在实验性自身免疫性脑脊髓炎(EAE)中的关键调控作用，提示靶向p40的治疗潜力。
---
注：上述文献为示例，实际引用时需核对期刊名称、年份及作者信息准确性。
The IL12B antibody targets interleukin-12 subunit beta (IL12B), a key component of the pro-inflammatory cytokines IL-12 and IL-23. IL12B, also known as p40. pairs with IL12A (p35) to form IL-12. and with IL23A (p19) to form IL-23. Both cytokines play critical roles in immune responses: IL-12 drives T-helper 1 (Th1) cell differentiation and interferon-γ production, while IL-23 promotes Th17-mediated inflammation. Dysregulation of these pathways is implicated in autoimmune diseases like psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD).
IL12B antibodies, such as ustekinumab, selectively block the p40 subunit, inhibiting IL-12 and IL-23 signaling. By neutralizing these cytokines, the antibodies reduce pathogenic Th1/Th17 responses and downstream pro-inflammatory mediators (e.g., TNF-α, IL-17). Ustekinumab, a human monoclonal IgG1 antibody, was the first IL12B-targeting biologic approved for moderate-to-severe plaque psoriasis (2009) and later for Crohn's disease and psoriatic arthritis.
Clinical trials demonstrate significant efficacy in reducing disease activity and improving patient outcomes. However, long-term safety monitoring remains essential due to potential infection risks linked to broad immune modulation. Ongoing research explores IL12B antibodies in other Th1/Th17-driven conditions, including multiple sclerosis and sarcoidosis, while newer biologics aim to refine targeting (e.g., dual IL-12/IL-23 inhibition vs. selective IL-23 blockade). This therapeutic approach highlights the central role of IL12B in chronic inflammation and its value as a drug target.
×
